ID: ALA3397809

Max Phase: Preclinical

Molecular Formula: C25H24F3NO3

Molecular Weight: 443.47

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1ccc(CN[C@@H]2CO[C@H](C(c3ccc(F)cc3)c3ccc(F)cc3)C[C@H]2O)cc1F

Standard InChI:  InChI=1S/C25H24F3NO3/c26-18-6-2-16(3-7-18)25(17-4-8-19(27)9-5-17)24-12-23(31)21(14-32-24)29-13-15-1-10-22(30)20(28)11-15/h1-11,21,23-25,29-31H,12-14H2/t21-,23-,24+/m1/s1

Standard InChI Key:  IPRLBMOCVKOGPV-JRFVFWCSSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 443.47

Molecular Weight (Monoisotopic): 443.1708

AlogP: 4.25

#Rotatable Bonds: 6

Polar Surface Area: 61.72

Molecular Species: NEUTRAL

HBA: 4

HBD: 3

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 8.60

CX Basic pKa: 7.92

CX LogP: 4.00

CX LogD: 3.68

Aromatic Rings: 3

Heavy Atoms: 32

QED Weighted: 0.53

Np Likeness Score: 0.06

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature